News
HRMY
31.59
-1.22%
-0.39
IXJ: Healthcare Sector Dashboard For March
IShares Global Healthcare ETF is overvalued by about 13% relative to 11-year averages. Healthcare equipment has the worst value and quality scores. The healthcare sector is the most overvalued in the U.S. In March 2024. This monthly article series shows a dashboard with aggregate industry metrics in healthcare.
Seeking Alpha · 16h ago
Weekly Report: what happened at HRMY last week (0311-0315)?
Weekly Report · 1d ago
Harmony Biosciences Holdings Breaks Above 200-Day Moving Average - Bullish for HRMY
NASDAQ · 3d ago
Weekly Report: what happened at HRMY last week (0304-0308)?
Weekly Report · 03/11 10:17
Weekly Report: what happened at HRMY last week (0226-0301)?
Weekly Report · 03/04 10:19
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Barchart · 02/28 07:05
Harmony Biosciences Price Target Cut to $40.00/Share From $42.00 by Mizuho
Dow Jones · 02/27 15:54
Harmony Biosciences Is Maintained at Buy by Mizuho
Dow Jones · 02/27 15:54
Mizuho Maintains Buy on Harmony Biosciences, Lowers Price Target to $40
Benzinga · 02/27 15:43
Weekly Report: what happened at HRMY last week (0219-0223)?
Weekly Report · 02/26 10:27
Harmony Biosciences Price Target Maintained With a $49.00/Share by Cantor Fitzgerald
Dow Jones · 02/23 17:30
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
Benzinga · 02/23 17:20
HRMY vs. TECH: Which Stock Is the Better Value Option?
NASDAQ · 02/23 16:40
Validea Joel Greenblatt Strategy Daily Upgrade Report - 2/23/2024
NASDAQ · 02/23 10:58
Harmony Biosciences Price Target Cut to $50.00/Share From $53.00 by Needham
Dow Jones · 02/23 10:54
Harmony Biosciences Is Maintained at Buy by Needham
Dow Jones · 02/23 10:54
Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $50
Benzinga · 02/23 10:44
Harmony Biosciences Holdings Inc reports results for the quarter ended in December - Earnings Summary
Harmony Biosciences Holdings Inc reports quarterly adjusted earnings of 45 cents per share for the quarter ended in December. Revenue rose 31.3% to $168.41 million from a year ago. The company reported quarterly income of $26.61 million.
Reuters · 02/23 03:00
Analyst Ratings For Harmony Biosciences
4 analysts have shared their evaluations of Harmony Biosciences (NASDAQ:HRMY) during the recent three months. The company is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. The analysts have established 12-month price targets of $38.25 for the company. The average price target has increased by 31.9% in the last three months to $53.00.
Benzinga · 02/22 16:00
Harmony Biosciences Price Target Maintained With a $53.00/Share by Needham
Dow Jones · 02/22 13:57
More
Webull provides a variety of real-time HRMY stock news. You can receive the latest news about Harmony Biosciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases, as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a molecule with a mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a major wake-promoting neurotransmitter. The Company also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. Its product candidates also include Zygel, which is a synthetic cannabidiol.